TY - JOUR
T1 - Work ability following breast cancer - the MyHealth randomized controlled trial
AU - Horsbøl, Trine A.
AU - Saltbæk, Lena
AU - Urhammer, Caroline
AU - Karlsen, Randi V.
AU - Johansen, Christoffer
AU - Bidstrup, Pernille E.
AU - Høeg, Beverley L.
AU - Zoffmann, Vibeke
AU - Belmonte, Federica
AU - Andersen, Ingelise
AU - Friberg, Anne S.
AU - Svendsen, Mads N.
AU - Christensen, Helle G.
AU - Glavicic, Vesna
AU - Nielsen, Dorte L.
AU - Dalton, Susanne O.
PY - 2025
Y1 - 2025
N2 - BACKGROUND AND PURPOSE: We previously demonstrated positive effects on quality of life and mental health following breast cancer when comparing a nurse-led follow-up program without scheduled visits (MyHealth) to regular follow-up. This study aims to examine whether MyHealth also positively impacts self-reported work ability. PATIENTS/MATERIAL AND METHODS: A total of 288 patients, potentially active on the labour market, were randomized to MyHealth or control follow-up after primary treatment for early-stage breast cancer (2017-2019). MyHealth included individual self-management sessions, electronic symptom monitoring, and assistance with navigating healthcare services. Control follow-up consisted of biannual outpatient visits with a physician. Linear mixed-effect models were applied to evaluate the effect of MyHealth on self-reported work ability at 6, 12, 24, and 36 months after randomization as measured by the Work Ability Score (WAS). RESULTS: Work ability increased significantly in both groups during the first 6 months (mean WAS increase MyHealth: 1.64, 95% confidence interval [CI]: 1.26; 2.02 and control: 1.57, 95% CI: 1.17; 1.97) and continued to increase slightly but non-significantly (p-values > 0.13) until end of follow-up at 36 months. Improvement was especially pronounced among patients reporting poor work ability at baseline. Differences in mean WAS between patients in MyHealth and control follow-up were non-significant and close to zero at all time points (-0.21 to 0.48). INTERPRETATION: The MyHealth follow-up program had no additional effect on self-reported work ability compared to regular follow-up. Future interventions should target patients with poor work ability and include components specifically designed to enhance work ability.
AB - BACKGROUND AND PURPOSE: We previously demonstrated positive effects on quality of life and mental health following breast cancer when comparing a nurse-led follow-up program without scheduled visits (MyHealth) to regular follow-up. This study aims to examine whether MyHealth also positively impacts self-reported work ability. PATIENTS/MATERIAL AND METHODS: A total of 288 patients, potentially active on the labour market, were randomized to MyHealth or control follow-up after primary treatment for early-stage breast cancer (2017-2019). MyHealth included individual self-management sessions, electronic symptom monitoring, and assistance with navigating healthcare services. Control follow-up consisted of biannual outpatient visits with a physician. Linear mixed-effect models were applied to evaluate the effect of MyHealth on self-reported work ability at 6, 12, 24, and 36 months after randomization as measured by the Work Ability Score (WAS). RESULTS: Work ability increased significantly in both groups during the first 6 months (mean WAS increase MyHealth: 1.64, 95% confidence interval [CI]: 1.26; 2.02 and control: 1.57, 95% CI: 1.17; 1.97) and continued to increase slightly but non-significantly (p-values > 0.13) until end of follow-up at 36 months. Improvement was especially pronounced among patients reporting poor work ability at baseline. Differences in mean WAS between patients in MyHealth and control follow-up were non-significant and close to zero at all time points (-0.21 to 0.48). INTERPRETATION: The MyHealth follow-up program had no additional effect on self-reported work ability compared to regular follow-up. Future interventions should target patients with poor work ability and include components specifically designed to enhance work ability.
U2 - 10.2340/1651-226X.2025.42221
DO - 10.2340/1651-226X.2025.42221
M3 - Journal article
C2 - 39775013
AN - SCOPUS:85215090532
SN - 1100-1704
VL - 64
SP - 34
EP - 39
JO - Acta oncologica (Stockholm, Sweden)
JF - Acta oncologica (Stockholm, Sweden)
ER -